Brain delivery of AAV9 expressing an anti-PrP monovalent antibody delays prion disease in mice

Prion

Volumn 6, Issue 4, 2012, Pages 383-390

  Moda, Fabio ^a   Vimercati, Chiara ^a   Campagnani, Ilaria ^a   Ruggerone, Margherita ^a   Giaccone, Giorgio ^a   Morbin, Michela ^a   Zentilin, Lorena ^b   Giacca, Mauro ^b   Zucca, Ileana ^a   Legname, Giuseppe ^c,d   Tagliavini, Fabrizio ^a  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

^b INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

^c SISSA   (Italy)

^d SINCROTRONE TRIESTE   (Italy)

Author keywords

AAV9; Immunotherapy; Monovalent antibody; Neurodegeneration; Prion disease

Indexed keywords

PARVOVIRUS VECTOR; PRION PROTEIN; PRION PROTEIN ANTIBODY; RECOMBINANT ADENO ASSOCIATED VIRAL VECTOR SEROTYPE 9; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE D18 PRION PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; INFECTION PREVENTION; MOUSE; NONHUMAN; SCRAPIE; TREATMENT OUTCOME;

ADENOVIRIDAE; ANIMALS; BRAIN; GENETIC VECTORS; HEK293 CELLS; HUMANS; MICE; PLASMIDS; PRIONS; SCRAPIE; SINGLE-CHAIN ANTIBODIES;

ANIMALIA; MUS;

EID: 84866537161     PISSN: 19336896     EISSN: 1933690X     Source Type: Journal    
DOI: 10.4161/pri.20197     Document Type: Article

References (38)

1. Prusiner SB. Molecular biology of prion diseases. Science 1991; 252:1515-22; PMID:1675487; http://dx.doi.org/10.1126/science.1675487.
2. Jendroska K, Heinzel FP, Torchia M, Stowring L, Kretzschmar HA, Kon A, et al. Proteinase-resistant prion protein accumulation in Syrian hamster brain correlates with regional pathology and scrapie infectivity. Neurology 1991; 41:1482-90; PMID:1679911.
3. Schenk D, Seubert P, Ciccarelli RB. Immunotherapy w 421 ith beta-amyloid for Alzheimer's disease: a new frontier. DNA Cell Biol 2004; 20:679-81; http://dx.doi.org/10.1089/10445490152717532.
4. Sigurdsson EM, Scholtzova H, Mehta PD, Frangione B, Wisniewski T. Immunization with a nontoxic/nonfibrillar amyloid-β homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. Am J Pathol 2001; 159:439-47; PMID:11485902; http://dx.doi.org/10.1016/S0002-9440(10)61715- 4.
5. Gabizon R, McKinley MP, Groth D, Prusiner SB. Immunoaffinity purification and neutralization of scrapie prion infectivity. Proc Natl Acad Sci USA 1988; 85:6617-21; PMID:3137571; http://dx.doi.org/10.1073/pnas.85.18.6617.
6. Sigurdsson EM, Brown DR, Daniels M, Kascsak RJ, Kascsak R, Carp R, et al. Immunization delays the onset of prion disease in mice. Am J Pathol 2002; 161:13-7; PMID:12107084; http://dx.doi.org/10.1016/S0002-9440(10)64151-X.
7. Polymenidou M, Heppner FL, Pellicioli EC, Urich E, Miele G, Braun N, et al. Humoral immune response to native eukaryotic prion protein correlates with anti-prion protection. Proc Natl Acad Sci USA 2004; 101:14670-6; PMID:15292505; http://dx.doi.org/10.1073/pnas.0404772101.
8. White AR, Enever P, Tayebi M, Mushens R, Linehan J, Brandner S, et al. Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature 2003; 422:80-3; PMID:12621436; http://dx.doi.org/10.1038/ nature01457.
9. Müller-Schiffmann A, Korth C. Vaccine approaches to prevent and treat prion infection: progress and challenges. Bio Drugs 2008; 22:45-52; PMID:18215090; http://dx.doi.org/10.2165/00063030-200822010-00005.
10. Solforosi L, Criado JR, McGavern DB, Wirz S, Sánchez-Alavez M, Sugama S, et al. Cross-linking cellular prion protein triggers neuronal apoptosis in vivo. Science 2004; 303:1514-6; PMID:14752167; http://dx.doi.org/ 10.1126/science.1094273.
11. Klöhn PC, Farmer M, Linehan JM, O'Malley C, Fernandez de Marco M, Taylor W, et al. PrP antibodies do not trigger mouse hippocampal neuron apoptosis. Science 2012; 335:52; PMID:22223800; http://dx.doi.org/10.1126/ science.1215579.
12. Campana V, Zentilin L, Mirabile I, Kranjc A, Casanova P, Giacca M, et al. Development of antibody fragments for immunotherapy of prion diseases. Biochem J 2009; 418:507-15; PMID:19000036; http://dx.doi.org/10.1042/BJ20081541.
13. Wuertzer CA, Sullivan MA, Qiu X, Federoff HJ. CNS delivery of vectored prion-specific single-chain antibodies delays disease onset. Mol Ther 2008; 16:481-6; PMID:18180775; http://dx.doi.org/10.1038/sj.mt.6300387.
14. Burger C, Nash K, Mandel RJ. Recombinant adeno-associated viral vectors in the nervous system. Hum Gene Ther 2005; 16:781-91; PMID:16000060; http://dx.doi.org/10.1089/hum.2005.16.781.
15. Mandel RJ, Manfredsson FP, Foust KD, Rising A, Reimsnider S, Nash K, et al. Recombinant adeno-associated viral vectors as therapeutic agents to treat neurological disorders. Mol Ther 2006; 13:463-83; PMID:16412695; http://dx.doi.org/10.1016/j.ymthe.2005.11.009.
16. Guenther K, Deacon RM, Perry VH, Rawlins JN. Early behavioural changes in scrapie-affected mice and the influence of dapsone. Eur J Neurosci 2001; 14:401-9; PMID:11553290; http://dx.doi.org/10.1046/j.0953-816x.2001.01645.x.
17. Cearley CN, Wolfe JH. Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9 and Rh10 in the mouse brain. Mol Ther 2006; 13:528-37; PMID:16413228; http://dx.doi.org/10.1016/j.ymthe.2005.11. 015.
18. Lasmézas CI, Deslys JP, Robain O, Jaegly A, Beringue V, Peyrin JM, et al. Transmission of the BSE agent to mice in the absence of detectable abnormal prion protein. Science 1997; 275:402-5; PMID:8994041; http://dx.doi.org/10.1126/science.275.5298.402.
19. Manson JC, Jamieson E, Baybutt H, Tuzi NL, Barron R, McConnell I, et al. A single amino acid alteration (101L) introduced into murine PrP dramatically alters incubation time of transmissible spongiform encephalopathy. EMBO J 1999; 18:6855-64; PMID:10581259; http://dx.doi.org/10.1093/emboj/18.23.6855.
20. Sc in vivo. J Biol Chem 2007; 282:35878-86; PMID:17923484; http://dx.doi.org/10.1074/jbc.M704329200.
21. Cronier S, Gros N, Tattum MH, Jackson GS, Clarke AR, Collinge J, et al. Detection and characterization of proteinase K-sensitive disease-related prion protein with thermolysin. Biochem J 2008; 416:297-305; PMID:18684106; http://dx.doi.org/10.1042/BJ20081235.
22. Gauczynski S, Hundt C, Leucht C, Weiss S. Interaction of prion proteins with cell surface receptors, molecular chaperones, and other molecules. Adv Protein Chem 2001; 57:229-72; PMID:11447692; http://dx.doi.org/10.1016/S0065- 3233(01)57024-2.
23. Supattapone S. Biochemistry. What makes a prion infectious? Science 2010; 327:1091-2; PMID:20185716; http://dx.doi.org/10.1126/science.1187790.
24. Akache B, Grimm D, Pandey K, Yant SR, Xu H, Kay MA. The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3 and 9. J Virol 2006; 80:9831-6; PMID:16973587; http://dx.doi.org/10.1128/JVI.00878- 06.
25. Foust KD, Nurre E, Montgomery CL, Hernandez A, Chan CM, Kaspar BK. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 2009; 27:59-65; PMID:19098898; http://dx.doi.org/10.1038/nbt. 1515.
26. Fields RD, Stevens-Graham B. New insights into neuron-glia communication. Science 2002; 298:556-62; PMID:12386325; http://dx.doi.org/10.1126/science.298. 5593.556.
27. Gray SJ, Matagne V, Bachaboina L, Yadav S, Ojeda SR, Samulski RJ. Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. Mol Ther 2011; 19:1058-69; PMID:21487395; http://dx.doi.org/10.1038/mt.2011.72.
28. Wang YJ, Gao CY, Yang M, Liu XH, Sun Y, Pollard A, et al. Intramuscular delivery of a single chain antibody gene prevents brain Aβ deposition and cognitive impairment in a mouse model of Alzheimer's disease. Brain Behav Immun 2010; 24:1281-93; PMID:20595065; http://dx.doi.org/10.1016/j.bbi.2010.05.010.
29. Henriques A, Pitzer C, Dittgen T, Klugmann M, Dupuis L, Schneider A. CNS-targeted viral delivery of G-CSF in an animal model for ALS: improved efficacy and preservation of the neuromuscular unit. Mol Ther 2011; 19:284-92; PMID:21139572; http://dx.doi.org/10.1038/mt.2010.271.
30. Southwell AL, Ko J, Patterson PH. Intrabody gene therapy ameliorates motor, cognitive and neuropathological symptoms in multiple mouse models of Huntington's disease. J Neurosci 2009; 29:13589-602; PMID:19864571; http://dx.doi.org/10.1523/JNEUROSCI.4286-09.2009.
31. Mochizuki H, Mizuno Y. Gene therapy for Parkinson's disease. J Neural Transm Suppl 2003; 65:205-13; PMID:12946058.
32. Muramatsu S, Fujimoto K, Kato S, Mizukami H, Asari S, Ikeguchi K, et al. A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease. Mol Ther 2010; 18:1731-5; PMID:20606642; http://dx.doi.org/10.1038/mt.2010.135.
33. Gao G, Vandenberghe LH, Alvira MR, Lu Y, Calcedo R, Zhou X, et al. Clades of Adeno-associated viruses are widely disseminated in human tissues. J Virol 2004; 78:6381-8; PMID:15163731; http://dx.doi.org/10.1128/JVI.78.12.6381-8.2004.
34. Zentilin L, Marcello A, Giacca M. Involvement of cellular double-stranded DNA break binding proteins in processing of the recombinant adeno-associated virus genome. J Virol 2001; 75:12279-87; PMID:11711618; http://dx.doi.org/10. 1128/JVI.75.24.12279-87.2001.
35. Outram GW. Changes in drinking and feeding habits of mice with experimental scrapie. J Comp Pathol 1972; 82:415-27; PMID:4630696; http://dx.doi.org/10.1016/0021-9975(72)90041-2.
36. Giaccone G, Canciani B, Puoti G, Rossi G, Goffredo D, Iussich S, et al. Creutzfeldt-Jakob disease: Carnoy's fixative improves the immunohistochemistry of the proteinase K-resistant prion protein. Brain Pathol 2000; 10:31-7; PMID:10668893; http://dx.doi.org/10.1111/j.1750-3639.2000.tb00240.x.
37. Fraser H, Dickinson AG. The sequential development of the brain lesion of scrapie in three strains of mice. J Comp Pathol 1968; 78:301-11; PMID:4970192; http://dx.doi.org/10.1016/0021-9975(68)90006-6.
38. Taraboulos A, Jendroska K, Serban D, Yang SL, DeArmond SJ, Prusiner SB. Regional mapping of prion proteins in brain. Proc Natl Acad Sci USA 1992; 89:7620-4; PMID:1354357; http://dx.doi.org/10.1073/pnas.89.16.7620.